Introduction
Currently, there are a number of novel molecular tools that are attracting the interest of urologists. The most important of these are immunohistochemistry (including a variety of antibody-based detection methods), in situ hybridization, and reverse transcriptase-polymerase chain reaction (RT-PCR). The following paper will focus on RT-PCR and its potential use in clinical urology.
Reverse transcriptase-polymerase chain reaction: a potential clinical tool PCR can be regarded as simply a method of amplifying the number of a particular deoxyribonucleic acid (DNA) target molecule that one would like to detect. After a number of rounds of replication (cycles), there will be an enrichment of several thousand-fold of that DNA. The ®rst step for PCR is denaturation of the DNA; then speci®c primers (short DNA fragments) are added that will hybridize to each end of the DNA to be ampli®ed. Synthesis then extends the primers. This process of ampli®cation generates enough molecules to make their detection by electrophoresis and subsequent staining simple. However, there is a methodological problem that prevents PCR from being applied directly to biological samples. PCR works only with DNA and, if researchers are interested in cell function, the cells have to be monitored for expression of messenger ribonucleic acid (mRNA).
Fortunately, this can be solved in a straightforward manner by using reverse-transcriptase to convert mRNA to complementary DNA (cDNA) before carrying out the ampli®cation step. RT-PCR can be used for a variety of purposes, including detection of malignant cells in peripheral blood, lymph node or bone marrow or marker molecule expression in carcinoma samples, as well as quanti®cation of the molecules expressed. This approach has proved so useful that it has become of great interest to both patients and clinicians, and both would like to see this method put into practice to help improve the accuracy of current prognostic methods and to help in the design of better treatment strategies. In order to become more widely adopted by clinicians, RT-PCR has to ful®l a number of speci®c criteria. It must be an easy to perform, fast and a reproducible test. In this regard, developing a method with a well-balanced sensitivity is of particular importance, as RT-PCR is so sensitive that it can easily detect cells at concentrations at which they have no clinical relevance. Thus, of most interest to clinicians would be a test which only gives positive results where there are over 10 4 10E4 circulating cells present, which incidentally represents the number of cells that one assumes can be eliminated by the immune system.
Selection of published data on RT-PCR for the detection of circulating cells in peripheral blood
Turning to the published literature on this molecular method, a recent paper by Ellis et al 1 provided some interesting results on applying RT-PCR to peripheral blood. These authors showed that only 1/56 patients (1.8%) gave a positive reaction in a test for prostate cancer and that, of those patients suspected of having prostate cancer but found to be negative on biopsy, 18.5% were found to be positive by RT-PCR. More interestingly, there was no difference between stage pT2 and pT3 patients and no correlation with pathological TNM staging. Even more worrisome was the ®nding that, in a group of seven patients who experienced rapid progression after undergoing radical retropubic prostatectomy (RRP), six had tested negative pre-operatively.
In contrast, in a study monitoring PSA/PSM-positive circulating cells, Zhang et al 2 reported a 100% positive response for both markers in bony metastasis, while in clinically localized cases the corresponding ®gure was only 29%. With regard to prediction of extracapsular penetration, calculation of the associated odds ratio (OR) produced a value of 20. In this regard, at a meeting of the German Urological Association in 1998, RT-PCR results for 120 pre-operative samples obtained from prostate cancer patients scheduled for RRP and nine samples of peripheral blood from patients with proven metastatic disease were presented by our own group (Table 1) . In carrying out RT-PCR analysis, Kawakami et al found that the speci®city of the assay could be markedly improved by incorporating the use of another marker, human glandular kallikrein (hK2). 3 However, even using both markers, only 9% of patients were positive with stage pT2c prior to radical prostatectomy, while 22% of patients with stage pT3a, and 100% of patients with distant metastasis, were found to be positive.
Finally, an important aspect to be mentioned is that the high sensitivity of the RT-PCR method is often combined with decreased speci®city. Therefore, precautions are necessary to exclude arti®cial positive results based on transcripts from cells of non-prostatic origin. 4, 5 Technical problems associated with the use of RT-PCR and possible solutions
The main problem associated with the use of RT-PCR in blood or bone marrow samples is a lack of inter-laboratory standardization, which makes it dif®cult to compare the results obtained by different groups. Given the fact that, at present, every group uses a different assay with a different sensitivity and speci®city from every other, progress in standardization is likely to be slow. However, there are a number of possible diagnostic and prognostic markers that can be monitored in tissue samples using speci®c antibodies or molecular approaches including RT-PCR. 4, 6, 7 In our own work the macrophage migration inhibitory factor (MIF), insulin-like growth factor receptor I (IGFR1), neutral endopeptidase (NEP), basic ®broblast growth factor binding-protein (bFGF-bp) and the bcl 2/ bax ratio are receiving the most attention.
If one wants to investigate a certain mRNA expression in cancerous tissue samples, one has to ®nd a feasible and reliable method to quantify the mRNA of interest. The theoretical course of PCR postulates that, being an exponential reaction, from the number of PCR cycles performed one can calculate the number of molecules present in the cup before the PCR reaction was started (Figure 1 ). In reality, however, the curve exhibits saturation, and after only a few cycles it becomes impossible to calculate back to time zero (Figure 2) . However, there are ways to quantify RT-PCR, including the use of endogenous RNA of housekeeping genes to compare the message in question with the message that is always expressed at the same level. Alternatively, arti®cial molecules can be synthesized as RNA or DNA standards, and competitive RT-PCR can be performed since these arti®cial molecules will not be present endogenously in the samples ( Figure  3) . In our experience, the use of RNA standards has been found to be the most accurate in quanti®cation of RT-PCR. One hundred and twenty pre-operative samples were obtained from patients scheduled for radical retropubic prostatectomy (RRP) and nine samples from patients with proven metastatic disease. Figure 2 The real pro®le of a PCR exhibits a saturation plateau after a certain number of cycles and it becomes impossible to quantify the initial target molecules. Figure 1 The theoretical course of a PCR is an exponential reaction depending on the number of PCR cycles performed. Therefore, the number of initial target molecules can be calculated as
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Summary
In summarizing our ®ndings at present, it appears that RT-PCR offers the clinician the ability to detect suspicious cells and mRNA expression which cannot be determined by other methods. Thus, the technique represents a very useful tool to assist in clinical decision-making. Its application is expected to expand rapidly, particularly if the standardization problems can be overcome. It is hoped, therefore, that combination of RT-PCR molecular tumorpro®ling with classic pathological diagnosis will markedly improve prediction of patient prognosis. In addition, markers associated with an adverse prognosis, which can be identi®ed by RT-PCR, could be potential candidates for a variety of immuno-and gene-therapeutic approaches. Figure 3 Approaches to quantifying RT-PCR of certain genes include the use of endogenous housekeeping gene RNA (1) or the addition of arti®cial RNA standards with known concentration prior to reverse transcription (2) . Alternatively, DNA standards can be used as direct competitor during the PCR ampli®cation (3). These RNA or DNA standards are longer or shorter than the endogenous target but bear the same oligo-nucleotide binding sites. After gel electrophoresis the ratio of standard and endogenous target amplicons can be calculated and quanti®ed.
